News

The approved therapy Taltz (ixekizumab) can effectively ease symptoms of ankylosing spondylitis and related forms of arthritis that affect the spine, a new analysis shows. The study, “The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis,”…

Adults with ankylosing spondylitis and other forms of arthritis are significantly less likely to be employed than people without arthritis, according to a new analysis from the U.K. Results suggest the effect of arthritis on employment is especially pronounced in certain demographic groups, particularly women and people without college…

Ankylosing spondylitis (AS) patients 65 and older may be at an increased risk of certain blood cancers compared with older adults in the general population, according to a recent study. The risk for these cancers, however, was similar among AS patients and people with another inflammatory condition called inflammatory…

Amgen’s Amjevita, the first biosimilar to Humira (adalimumab) to receive approval by the U.S. Food and Drug Administration, is now available in the U.S. for the treatment of ankylosing spondylitis (AS) and other diseases. While the medication was initially approved in 2016, Amjevita is only now reaching…

Smoking and alcohol consumption are both associated with lower rates of peripheral symptoms in people with spondyloarthritis, which includes ankylosing spondylitis, a new study reports. The findings were somewhat surprising, researchers noted, as smoking has been linked to a greater risk of developing certain rheumatic diseases, and with more…

The ratio of two blood proteins, fibrinogen and albumin, accurately measures inflammation severity with different types of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study showed. The accuracy of this biomarker closely matched those of standard inflammatory markers used in research and clinical practice. Further studies are needed to…

A year of treatment with bimekizumab was safe and significantly eased symptoms of ankylosing spondylitis (AS) in participants of two Phase 3 clinical trials, regardless of whether they had been treated previously with inhibitors of the pro-inflammatory molecule TNF. “Treatment with bimekizumab resulted in rapid and clinically relevant…

Alvotech has launched a Phase 1 clinical trial to test the safety and efficacy of AVT05, its biosimilar drug candidate to Simponi (golimumab) — being developed for the treatment of ankylosing spondylitis (AS) and other diseases marked by inflammation. The study (NCT05632211) is enrolling more than…

Health Canada has approved a high-concentration formulation of Hadlima (adalimumab-bwwd), a biosimilar to Humira (adalimumab), for treating ankylosing spondylitis (AS) and other diseases. A biosimilar is a medical product designed to be identical — with similar properties, as well as comparable safety and effectiveness — to an…

Some immune T-cells that react to microbial proteins also target normal human proteins in people who carry HLA-B27 variants, the strongest genetic risk factor contributing to ankylosing spondylitis (AS), a study revealed. The shape of the protein fragments targeted by the immune T-cells, whether human or bacterial, was almost…